Opus Genetics (NASDAQ:IRD – Get Free Report) and Kura Oncology (NASDAQ:KURA – Get Free Report) are both small-cap healthcare companies, but which is the superior investment? We will compare the two businesses based on the strength of their analyst recommendations, earnings, institutional ownership, dividends, profitability, risk and valuation.
Insider and Institutional Ownership
15.0% of Opus Genetics shares are held by institutional investors. 11.7% of Opus Genetics shares are held by insiders. Comparatively, 7.6% of Kura Oncology shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.
Profitability
This table compares Opus Genetics and Kura Oncology’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Opus Genetics | -1,091.82% | N/A | -150.13% |
| Kura Oncology | -384.30% | -207.18% | -45.17% |
Earnings and Valuation
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Opus Genetics | $14.20 million | 23.34 | -$49.59 million | ($1.35) | -2.97 |
| Kura Oncology | $67.48 million | 8.96 | -$278.67 million | ($3.37) | -2.02 |
Opus Genetics has higher earnings, but lower revenue than Kura Oncology. Opus Genetics is trading at a lower price-to-earnings ratio than Kura Oncology, indicating that it is currently the more affordable of the two stocks.
Risk & Volatility
Opus Genetics has a beta of 0.8, meaning that its share price is 20% less volatile than the S&P 500. Comparatively, Kura Oncology has a beta of 0.56, meaning that its share price is 44% less volatile than the S&P 500.
Analyst Ratings
This is a summary of current recommendations for Opus Genetics and Kura Oncology, as reported by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Opus Genetics | 1 | 1 | 16 | 1 | 2.89 |
| Kura Oncology | 1 | 1 | 11 | 0 | 2.77 |
Opus Genetics presently has a consensus target price of $12.71, indicating a potential upside of 217.06%. Kura Oncology has a consensus target price of $25.35, indicating a potential upside of 272.84%. Given Kura Oncology’s higher possible upside, analysts clearly believe Kura Oncology is more favorable than Opus Genetics.
Summary
Opus Genetics beats Kura Oncology on 10 of the 14 factors compared between the two stocks.
About Opus Genetics
Opus Genetics Inc. is a clinical-stage ophthalmic biopharmaceutical company, focuses on developing and commercializing therapies for the treatment of unmet needs of patients with refractive and retinal eye disorders. Opus Genetics Inc., formerly known as Ocuphire Pharma Inc., is based in Farmington Hills, Michigan.
About Kura Oncology
Kura Oncology, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. The company’s pipeline consists of small molecule product candidates that target cancer. Its lead product candidates are ziftomenib, an orally bioavailable small molecule inhibitor of the menin-KMT2A interaction for the treatment of genetically defined subsets of acute leukemias, including acute myeloid leukemia and acute lymphoblastic leukemia; tipifarnib, an orally bioavailable farnesyl transferase inhibitor combination with alpelisib for patients with PIK3CA-dependent HNSCC; and KO-2806, a farnesyl transferase inhibitor for the treatment of solid tumors. It has a clinical collaboration with Novartis Pharma AG to evaluate the combination of tipifarnib and alpelisib in patients with head and neck squamous cell carcinoma whose tumors have HRAS overexpression and/or PIK3CA mutation and/or amplification. The company was founded in 2014 and is headquartered in San Diego, California.
Receive News & Ratings for Opus Genetics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Opus Genetics and related companies with MarketBeat.com's FREE daily email newsletter.
